Printer Friendly

Research and Markets: Malignant Neoplasms - Pipeline Review, H2 2012.

DUBLIN -- Research and Markets ( has announced the addition of Global Markets Direct's new report "Malignant Neoplasms - Pipeline Review, H2 2012" to their offering.

Global Markets Direct's, 'Malignant Neoplasms - Pipeline Review, H2 2012', provides an overview of the Malignant Neoplasms therapeutic pipeline. This report provides information on the therapeutic development for Malignant Neoplasms, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Malignant Neoplasms. 'Malignant Neoplasms - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.


- A snapshot of the global therapeutic scenario for Malignant Neoplasms.

- A review of the Malignant Neoplasms products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Malignant Neoplasms pipeline on the basis of route of administration and molecule type.

- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.

- Key discontinued pipeline projects.

- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Malignant Neoplasms.

- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.

- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.

- Devise corrective measures for pipeline projects by understanding Malignant Neoplasms pipeline depth and focus of Malignant Neoplasms therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

For more information visit

Source: Global Markets Direct
COPYRIGHT 2012 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Sep 6, 2012
Previous Article:Research and Markets: Smartphone Futures 2012-2016: Worldwide Market Analysis and Competitor Positioning in the High-End Handset Market.
Next Article:McDonalds, FedEx, Citi, Coca-Cola and Southwest Airlines among 20+ corporate industry leaders to join Useful Social Media this October to debate how...

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters